In this study, we have found for the first time that silencing of pro-oncogenic RUNX2 in p53-deficient pancreatic cancer AsPC-1 cells helps to amplify TAp63 response to GEM and bolsters its tumor-suppressive function. Here, TP53 is linked to neoplasm.